Bausch & LombBLCO +2.58%77 FCF Margin % is -5.47% as of Mar. 2026. GuruFocus rates BLCO with a GF Score™ of 77/100 and a GF Value™ of $18.60 (Modestly Undervalued). The stock has 8 warning signs investors should review. Among 815 Medical Devices & Instruments companies, Bausch & Lomb ranks better than 50.31% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Bausch & Lomb's Free Cash Flow for the
three
months ended in Mar. 2026 was $-68 Mil. Bausch & Lomb's Revenue for the
three
months ended in Mar. 2026 was $1,244 Mil. Therefore, Bausch & Lomb's FCF Margin % for the quarter that ended in Mar. 2026 was -5.47%.
The historical rank and industry rank for Bausch & Lomb's FCF Margin % or its related term are showing as below:
BLCO'
s FCF Margin % Range Over the Past 10 Years
Min: -4.78 Med: 6.11 Max: 18.06
Current: 0.02
During the past 8 years, the highest FCF Margin % of Bausch & Lomb was 18.06%. The lowest was -4.78%. And the median was 6.11%.
BLCO's FCF Margin % is ranked better than 50.31% of 815
companies
in the Medical Devices & Instruments industry
Industry Median: -0.03
vs BLCO: 0.02
Bausch & Lomb FCF Margin % Related Terms
Bausch & Lomb FCF Margin % Historical Data
* Premium members only.
The historical data trend for Bausch & Lomb's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Bausch & Lomb's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bausch & Lomb FCF Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bausch & Lomb's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Bausch & Lomb's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bausch & Lomb (BLCO) has a FCF Margin % of -5.47% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Bausch & Lomb and its competitors. According to the industry distribution chart, Bausch & Lomb ranks #405 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 49.7%.
Is Bausch & Lomb's FCF Margin % too high?
Bausch & Lomb's current FCF Margin % is -5.47%. Based on the distribution chart, Bausch & Lomb ranks #405 out of 815 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Bausch & Lomb has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bausch & Lomb's FCF Margin % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Bausch & Lomb ranks #405 out of 815 companies for FCF Margin %. This puts Bausch & Lomb in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Devices & Instruments company?
A good FCF Margin % depends on the Medical Devices & Instruments industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Bausch & Lomb and its competitors. Bausch & Lomb's current FCF Margin % is -5.47%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bausch & Lomb stock overvalued right now?
Based on GuruFocus' analysis, Bausch & Lomb (BLCO) is currently considered Modestly Undervalued. The stock's GF Value™ is $18.60, compared to a current price of $15.91 — trading 14.5% below its estimated fair value. The current FCF Margin % is -5.47%. Bausch & Lomb's overall GF Score™ is 77/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Bausch & Lomb (BLCO), the current FCF Margin % is -5.47% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bausch & Lomb (BLCO) Overvalued in 2026?
Based on GuruFocus' analysis, Bausch & Lomb stock appears to be undervalued.
The current stock price of $15.91 is trading 14.5% below its estimated GF Value™ of $18.60.
GuruFocus considers Bausch & Lomb to be Modestly Undervalued.
Key valuation signals for BLCO:
FCF Margin %: -5.47%
GF Value™: $18.60 vs. price of $15.91 (14.5% below fair value)
No single metric tells the full story. See the BLCO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
77GF Score
Get the complete analysis for BLCO
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BLCO has been successfully added to your 
